董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barbara Yanni | 女 | Director | 71 | 11.40万美元 | 17.75 | 2026-01-01 |
| Paul Sekhri | 男 | Chairperson | 68 | 9.56万美元 | 未持股 | 2026-01-01 |
| Sijmen de Vries | 男 | Chief Executive Officer,Executive Director | 66 | 195.80万美元 | 未持股 | 2026-01-01 |
| Leonard Kruimer | 男 | Director | 69 | 10.90万美元 | 15.26 | 2026-01-01 |
| Deborah Jorn | 女 | Vice Chairperson | 68 | 4.50万美元 | 未持股 | 2026-01-01 |
| Mark Pykett | 男 | Director | 62 | 10.00万美元 | 17.75 | 2026-01-01 |
| Jabine van der Meijs | 女 | Director | 60 | 11.40万美元 | 15.26 | 2026-01-01 |
| Steven Baert | 男 | Director | 52 | 5.10万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sijmen de Vries | 男 | Chief Executive Officer,Executive Director | 66 | 195.80万美元 | 未持股 | 2026-01-01 |
| Mireille Sanders | 女 | Chief Operations Officer | 57 | 未披露 | 123.24 | 2026-01-01 |
| Anurag Relan | 男 | Chief Medical Officer | 54 | 未披露 | 98.59 | 2026-01-01 |
| Ruud van Outersterp | 男 | Chief Ethics and Compliance Officer | 62 | 未披露 | 78.47 | 2026-01-01 |
| Leverne Marsh | 女 | Chief Commercial Officer | 55 | 未披露 | 未持股 | 2026-01-01 |
| Kenneth Lynard | 男 | Chief Financial Officer | 57 | 未披露 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Barbara Yanni
-
Barbara Yanni（2001年11月-2014年3月退休）担任Merck & Co（一家制药公司）副总裁和首席授权官。在这之前，她在Merck担任不同的职位，包括企业发展、财务评价、税收。她也在Symic Biomedical股份有限公司（Symic Biomedical, Inc，一家私人生物技术公司）董事会工作。她拥有斯坦福大学法学院（Stanford Law School）博士学位和韦尔斯利学院（Wellesley College）学士学位。她也拥有纽约大学（New York University）税收法律硕士学位。
Barbara Yanni has served as a Non Executive Director since December 2020 and is the Chair of the Transaction Committee, and a member of the Remuneration and Corporate Governance committees. Barbara currently serves on the Board of Directors of Trevena, Inc., and two private biotechnology companies, Mesentech and Delsona Therapeutics. She previously served on the boards of several biotechnology companies including Oncorus, Inc. (2021–2023) and Vaccinex (2015–2025). She spent nearly three decades at Merck & Co., including as Vice President and Chief Licensing Officer (2001–2014), after earlier roles spanning corporate development, financial evaluation, and tax strategy. She began her career as a tax lawyer in New York City. She earned a J.D. from Stanford Law School and an A.B. from Wellesley College, and holds an LL.M. in Taxation from New York University. - Barbara Yanni（2001年11月-2014年3月退休）担任Merck & Co（一家制药公司）副总裁和首席授权官。在这之前，她在Merck担任不同的职位，包括企业发展、财务评价、税收。她也在Symic Biomedical股份有限公司（Symic Biomedical, Inc，一家私人生物技术公司）董事会工作。她拥有斯坦福大学法学院（Stanford Law School）博士学位和韦尔斯利学院（Wellesley College）学士学位。她也拥有纽约大学（New York University）税收法律硕士学位。
- Barbara Yanni has served as a Non Executive Director since December 2020 and is the Chair of the Transaction Committee, and a member of the Remuneration and Corporate Governance committees. Barbara currently serves on the Board of Directors of Trevena, Inc., and two private biotechnology companies, Mesentech and Delsona Therapeutics. She previously served on the boards of several biotechnology companies including Oncorus, Inc. (2021–2023) and Vaccinex (2015–2025). She spent nearly three decades at Merck & Co., including as Vice President and Chief Licensing Officer (2001–2014), after earlier roles spanning corporate development, financial evaluation, and tax strategy. She began her career as a tax lawyer in New York City. She earned a J.D. from Stanford Law School and an A.B. from Wellesley College, and holds an LL.M. in Taxation from New York University.
- Paul Sekhri
-
Paul Sekhri，2019-2022：专注于移植的生物技术公司egenesis, Inc.的总裁兼首席执行官。2015-2019年：glycerol公司（专注于自身免疫性疾病的生物制药公司）总裁兼首席执行官。2016-2017年：运营合伙人，Highline Therapeutics，一家由Versant ventures推出的生物技术孵化器。2014-2015年：跨国制药公司赛诺菲（Sanofi s.a.）的高级副总裁，综合医疗。2013-2014年：全球制药公司Teva Pharmaceutical Industries, Ltd.集团执行副总裁，全球业务发展和首席战略官。2009-2013年：全球私人投资公司TPG capital旗下TPG Biotech的运营合伙人和生物技术运营集团负责人。2004-2009年：Cerimon Pharmaceuticals, Inc.（一家制药公司）的总裁兼首席执行官。Spring Discovery, Inc.， 2021-至今。Longboard Pharmaceuticals（2020年至今）（公众）。egenesis, Inc 。（2019年至今）。Ipsen S.A.（2018-至今）（公共）。Compugen Ltd.（2017-至今）（大众）。Pharming Group N.V。（2015年至今）（上市）。BiomX, Inc.（2020-2022）（大众）。Alpine Immune Sciences, Inc.（2017-2020）（公共）。马里兰大学动物学理学学士。马里兰大学医学院临床解剖学和神经科学研究生学习。
Paul Sekhri,currently serves as President and CEO of vTv Therapeutics Inc. (2022–present). Previously, he held CEO roles at eGenesis, Inc. (2019–2022), Lycera Corp. (2015–2019), and Cerimon Pharmaceuticals (2004–2009). His executive experience includes SVP of Integrated Care at Sanofi (2014–2015), Group EVP at Teva Pharmaceutical (2013–2014), and Operating Partner roles at TPG Biotech (2003–2013) and Hightine Therapeutics (2016–2017). He serves/has served on multiple public company boards including Compugen Ltd. (2017–present), Longboard Pharmaceuticals (2020–2024), and Ipsen S.A. (2018–2023). Sekhri holds a BS in Zoology from the University of Maryland and completed post-graduate studies in clinical anatomy and neuroscience at UMD School of Medicine. - Paul Sekhri，2019-2022：专注于移植的生物技术公司egenesis, Inc.的总裁兼首席执行官。2015-2019年：glycerol公司（专注于自身免疫性疾病的生物制药公司）总裁兼首席执行官。2016-2017年：运营合伙人，Highline Therapeutics，一家由Versant ventures推出的生物技术孵化器。2014-2015年：跨国制药公司赛诺菲（Sanofi s.a.）的高级副总裁，综合医疗。2013-2014年：全球制药公司Teva Pharmaceutical Industries, Ltd.集团执行副总裁，全球业务发展和首席战略官。2009-2013年：全球私人投资公司TPG capital旗下TPG Biotech的运营合伙人和生物技术运营集团负责人。2004-2009年：Cerimon Pharmaceuticals, Inc.（一家制药公司）的总裁兼首席执行官。Spring Discovery, Inc.， 2021-至今。Longboard Pharmaceuticals（2020年至今）（公众）。egenesis, Inc 。（2019年至今）。Ipsen S.A.（2018-至今）（公共）。Compugen Ltd.（2017-至今）（大众）。Pharming Group N.V。（2015年至今）（上市）。BiomX, Inc.（2020-2022）（大众）。Alpine Immune Sciences, Inc.（2017-2020）（公共）。马里兰大学动物学理学学士。马里兰大学医学院临床解剖学和神经科学研究生学习。
- Paul Sekhri,currently serves as President and CEO of vTv Therapeutics Inc. (2022–present). Previously, he held CEO roles at eGenesis, Inc. (2019–2022), Lycera Corp. (2015–2019), and Cerimon Pharmaceuticals (2004–2009). His executive experience includes SVP of Integrated Care at Sanofi (2014–2015), Group EVP at Teva Pharmaceutical (2013–2014), and Operating Partner roles at TPG Biotech (2003–2013) and Hightine Therapeutics (2016–2017). He serves/has served on multiple public company boards including Compugen Ltd. (2017–present), Longboard Pharmaceuticals (2020–2024), and Ipsen S.A. (2018–2023). Sekhri holds a BS in Zoology from the University of Maryland and completed post-graduate studies in clinical anatomy and neuroscience at UMD School of Medicine.
- Sijmen de Vries
-
Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom). - Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
- Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom).
- Leonard Kruimer
-
Leonard Kruimer在公司财务、规划和战略方面有30多年的经验，包括在私营和公开上市的生物技术和生命科学公司担任20多年的高级管理职务。值得注意的是，从1998年到2011年Crucell被强生公司收购，Kruimer先生担任Crucell的首席财务官和执行委员会成员。任职期间，他曾领导公司的融资活动，并促成Crucell公司以4.5亿美元战略收购总部位于瑞士的Berna Biotech公司。目前，Kruimer先生担任Zealand Pharma NASDAQ:ZEAL的独立董事兼审计委员会主席，是BioInvent AB（OMXS:BINV）的董事会主席，并在位于阿姆斯特丹的私募股权公司Karmijn Kapitaal Investments的投资咨询委员会任职。此前，他曾担任SkylinedX公司（DNA诊断公司）的首席财务官，也曾担任Profibrix公司的董事会主席（从2011年到2013年公司被The Medicines Company（NASDAQ:MDCO）收购）。2014年Kruimer先生担任Dutch Biotech BBB Therapeutics的临时首席执行官。任职Crucell公司之前，Kruimer曾担任Tip Europe公司（GE Capital公司）的董事总经理。他曾担任McKinsey&Company的顾问，并在纽约Price Waterhouse开始他的职业生涯。Kruimer先生拥有哈佛商学院（Harvard Business School）工商管理硕士学位，是纽约州的注册会计师。
Leonard Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011 when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma Nasdaq: ZEAL, and Chairman of the Board of BioInvent AB (OMXS: BINV). He is a director of Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Mr. Kruimer held various executive board positions on an interim basis. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard, a BA in accounting and finance from University of Massachusetts and is a CPA in New York State. - Leonard Kruimer在公司财务、规划和战略方面有30多年的经验，包括在私营和公开上市的生物技术和生命科学公司担任20多年的高级管理职务。值得注意的是，从1998年到2011年Crucell被强生公司收购，Kruimer先生担任Crucell的首席财务官和执行委员会成员。任职期间，他曾领导公司的融资活动，并促成Crucell公司以4.5亿美元战略收购总部位于瑞士的Berna Biotech公司。目前，Kruimer先生担任Zealand Pharma NASDAQ:ZEAL的独立董事兼审计委员会主席，是BioInvent AB（OMXS:BINV）的董事会主席，并在位于阿姆斯特丹的私募股权公司Karmijn Kapitaal Investments的投资咨询委员会任职。此前，他曾担任SkylinedX公司（DNA诊断公司）的首席财务官，也曾担任Profibrix公司的董事会主席（从2011年到2013年公司被The Medicines Company（NASDAQ:MDCO）收购）。2014年Kruimer先生担任Dutch Biotech BBB Therapeutics的临时首席执行官。任职Crucell公司之前，Kruimer曾担任Tip Europe公司（GE Capital公司）的董事总经理。他曾担任McKinsey&Company的顾问，并在纽约Price Waterhouse开始他的职业生涯。Kruimer先生拥有哈佛商学院（Harvard Business School）工商管理硕士学位，是纽约州的注册会计师。
- Leonard Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011 when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma Nasdaq: ZEAL, and Chairman of the Board of BioInvent AB (OMXS: BINV). He is a director of Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Mr. Kruimer held various executive board positions on an interim basis. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard, a BA in accounting and finance from University of Massachusetts and is a CPA in New York State.
- Deborah Jorn
-
Deborah Jorn自2019年以来一直担任董事。Jorn女士于2016年至2018年担任Eyepoint Pharmaceuticals公司和商业开发执行副总裁。加入Eyepoint公司之前，她曾担任Bausch Health公司（前身是Valeant Pharmaceuticals公司）的执行副总裁兼集团公司主席，在那里她曾领导皮肤科、胃肠病学和HAE业务。Jorn女士在Bausch&Lomb于2013年被Bausch Health收购之前曾担任Bausch&Lomb的首席全球营销官，在那里她领导了几种新产品的推出以及收购后对ISTA Pharmaceuticals的整合。此前，她曾担任Schering Plough Corporation的女性医疗保健和生育力集团副总裁（2008年至2010年）、过敏和呼吸系统集团董事（2004年至2008年）（被Merck and Co.，Inc.收购之前）。Jorn女士还在强生公司担任内科和早期商业投入的全球副总裁。她的职业生涯始于默克公司（Merck），并在各种职能领域（包括研发、监管和销售与市场营销）担任职务20多年。Jorn女士还担任ViveveMedical，Inc.董事会成员，并于2016年5月至2018年7月担任OrexigenTherapeutics，Inc.董事会成员。
Deborah Jorn has served as a director since 2019. Ms. Jorn was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals from 2016 to 2018. Prior to joining Eyepoint, she was Executive Vice President and Group Company Chair at Bausch Health formerly Valeant Pharmaceuticals where she led the dermatology, gastroenterology and HAE businesses. Ms. Jorn was Chief Global Marketing Officer at Bausch & Lomb prior to its acquisition in 2013 by Bausch Health where she led the launch of several new products and the integration of Ista Pharmaceuticals following acquisition. Previously, she was Group Vice President of Women’s Healthcare and Fertility (2008-2010) and Allergy and Respiratory (2004-2008) at Schering Plough Corporation prior to its acquisition by Merck and Co., Inc. Ms. Jorn was also at Johnson & Johnson as the Worldwide Vice President of Internal Medicine and Early Commercial input. She began her career at Merck and for more than 20 years held roles of progressive responsibility in various functional areas including R&D, Regulatory and Sales and Marketing. Ms. Jorn also serves on the board of directors of Viveve Medical, Inc. and she served as a member of the board of directors of Orexigen Therapeutics, Inc. from May 2016 until July 2018. - Deborah Jorn自2019年以来一直担任董事。Jorn女士于2016年至2018年担任Eyepoint Pharmaceuticals公司和商业开发执行副总裁。加入Eyepoint公司之前，她曾担任Bausch Health公司（前身是Valeant Pharmaceuticals公司）的执行副总裁兼集团公司主席，在那里她曾领导皮肤科、胃肠病学和HAE业务。Jorn女士在Bausch&Lomb于2013年被Bausch Health收购之前曾担任Bausch&Lomb的首席全球营销官，在那里她领导了几种新产品的推出以及收购后对ISTA Pharmaceuticals的整合。此前，她曾担任Schering Plough Corporation的女性医疗保健和生育力集团副总裁（2008年至2010年）、过敏和呼吸系统集团董事（2004年至2008年）（被Merck and Co.，Inc.收购之前）。Jorn女士还在强生公司担任内科和早期商业投入的全球副总裁。她的职业生涯始于默克公司（Merck），并在各种职能领域（包括研发、监管和销售与市场营销）担任职务20多年。Jorn女士还担任ViveveMedical，Inc.董事会成员，并于2016年5月至2018年7月担任OrexigenTherapeutics，Inc.董事会成员。
- Deborah Jorn has served as a director since 2019. Ms. Jorn was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals from 2016 to 2018. Prior to joining Eyepoint, she was Executive Vice President and Group Company Chair at Bausch Health formerly Valeant Pharmaceuticals where she led the dermatology, gastroenterology and HAE businesses. Ms. Jorn was Chief Global Marketing Officer at Bausch & Lomb prior to its acquisition in 2013 by Bausch Health where she led the launch of several new products and the integration of Ista Pharmaceuticals following acquisition. Previously, she was Group Vice President of Women’s Healthcare and Fertility (2008-2010) and Allergy and Respiratory (2004-2008) at Schering Plough Corporation prior to its acquisition by Merck and Co., Inc. Ms. Jorn was also at Johnson & Johnson as the Worldwide Vice President of Internal Medicine and Early Commercial input. She began her career at Merck and for more than 20 years held roles of progressive responsibility in various functional areas including R&D, Regulatory and Sales and Marketing. Ms. Jorn also serves on the board of directors of Viveve Medical, Inc. and she served as a member of the board of directors of Orexigen Therapeutics, Inc. from May 2016 until July 2018.
- Mark Pykett
-
Mark Pykett自2020年12月起担任董事。Pykett博士自2018年以来一直担任PtcTherapeutics，Inc.的首席科学官。从2014年到2018年被PTC Therapeutics收购，Pykett博士一直担任Agilis Biotherapeutics的总裁兼首席执行官。在加入Agilis之前，Pykett博士曾担任Navidea Biopharmaceuticals的首席执行官，Alseres Pharmaceuticals的总裁，Cygenics的总裁以及Cytomatrix的总裁兼首席执行官。Pykett博士拥有宾夕法尼亚大学分子生物学博士学位，宾夕法尼亚大学兽医学院VMD学位和安默斯特学院生物学学士学位。
Mark Pykett has served as a Non Executive Director since December 2020. He is Vice Chairman of the Board and a member of the Audit and Transaction committees. Mark is currently Chief Executive Officer and Director of Orogen Therapeutics and serves on the Board of the private company Myopax. He previously served as President and Chief Executive Officer of Myrtelle, Inc., Chief Scientific Officer of PTC Therapeutics, and President and Chief Executive Officer of Agilis Biotherapeutics until its acquisition by PTC Therapeutics in 2018. Earlier roles include CEO of Navidea Biopharmaceuticals and senior leadership positions at Alseres Pharmaceuticals, Cygenics, and Cytomatrix. He holds a Ph.D. in Molecular Biology and a V.M.D. from the University of Pennsylvania, a B.A. in Biology from Amherst College, and an MBA from Northeastern University. - Mark Pykett自2020年12月起担任董事。Pykett博士自2018年以来一直担任PtcTherapeutics，Inc.的首席科学官。从2014年到2018年被PTC Therapeutics收购，Pykett博士一直担任Agilis Biotherapeutics的总裁兼首席执行官。在加入Agilis之前，Pykett博士曾担任Navidea Biopharmaceuticals的首席执行官，Alseres Pharmaceuticals的总裁，Cygenics的总裁以及Cytomatrix的总裁兼首席执行官。Pykett博士拥有宾夕法尼亚大学分子生物学博士学位，宾夕法尼亚大学兽医学院VMD学位和安默斯特学院生物学学士学位。
- Mark Pykett has served as a Non Executive Director since December 2020. He is Vice Chairman of the Board and a member of the Audit and Transaction committees. Mark is currently Chief Executive Officer and Director of Orogen Therapeutics and serves on the Board of the private company Myopax. He previously served as President and Chief Executive Officer of Myrtelle, Inc., Chief Scientific Officer of PTC Therapeutics, and President and Chief Executive Officer of Agilis Biotherapeutics until its acquisition by PTC Therapeutics in 2018. Earlier roles include CEO of Navidea Biopharmaceuticals and senior leadership positions at Alseres Pharmaceuticals, Cygenics, and Cytomatrix. He holds a Ph.D. in Molecular Biology and a V.M.D. from the University of Pennsylvania, a B.A. in Biology from Amherst College, and an MBA from Northeastern University.
- Jabine van der Meijs
-
Jabine van der Meijs，自2021年起担任非执行董事。在此之前，她曾担任皇家史基浦集团执行副总裁兼CFO（2017年至2021年），并在荷兰皇家壳牌集团工作了25年，主要担任财务领导职位，但也在荷兰、苏格兰、英格兰、文莱和澳大利亚担任人力资源和战略职位。她最近在壳牌担任的职务是壳牌项目和技术业务的财务项目副总裁。van der Meijs女士还是V.Group Ltd（自2022年9月1日起）和VFS Global AG（自2023年1月1日起）的非执行董事。van der Meijs女士是Koole Terminals Holding B.V.监事会成员和Grundfos Holding A/S董事会成员。此前，van der Meijs女士曾在多个董事会担任非执行董事，包括Kendrion N.V.、Aeroports de Paris（France）和Brisbane Airport Corporation。van der Meijs女士拥有乌得勒支大学（University of Utrecht）的理学硕士（药学）和药学博士（Pharm D）学位，并在英国特许管理会计师协会（ACMA）完成了她的专业会计学位。
Jabine van der Meijs has served as a Non Executive Director since May 2021. She is Chair of the Corporate Governance Committee and a member of the Audit and Remuneration committees. She previously served as Executive Vice President and CFO of Royal Schiphol Group (2017–2021) and spent 25 years at Royal Dutch Shell, including as VP Finance Projects for Shell's Projects & Technology business. Jabine is a Non Executive Director at VFS Global AG and Grundfos Holding A/S and serves on the Supervisory Boards of Chane and the Centre for Human Drug Research. She holds a PharmD and an MSc (Pharmacy) from Utrecht University and is ACMA/CGMA qualified. - Jabine van der Meijs，自2021年起担任非执行董事。在此之前，她曾担任皇家史基浦集团执行副总裁兼CFO（2017年至2021年），并在荷兰皇家壳牌集团工作了25年，主要担任财务领导职位，但也在荷兰、苏格兰、英格兰、文莱和澳大利亚担任人力资源和战略职位。她最近在壳牌担任的职务是壳牌项目和技术业务的财务项目副总裁。van der Meijs女士还是V.Group Ltd（自2022年9月1日起）和VFS Global AG（自2023年1月1日起）的非执行董事。van der Meijs女士是Koole Terminals Holding B.V.监事会成员和Grundfos Holding A/S董事会成员。此前，van der Meijs女士曾在多个董事会担任非执行董事，包括Kendrion N.V.、Aeroports de Paris（France）和Brisbane Airport Corporation。van der Meijs女士拥有乌得勒支大学（University of Utrecht）的理学硕士（药学）和药学博士（Pharm D）学位，并在英国特许管理会计师协会（ACMA）完成了她的专业会计学位。
- Jabine van der Meijs has served as a Non Executive Director since May 2021. She is Chair of the Corporate Governance Committee and a member of the Audit and Remuneration committees. She previously served as Executive Vice President and CFO of Royal Schiphol Group (2017–2021) and spent 25 years at Royal Dutch Shell, including as VP Finance Projects for Shell's Projects & Technology business. Jabine is a Non Executive Director at VFS Global AG and Grundfos Holding A/S and serves on the Supervisory Boards of Chane and the Centre for Human Drug Research. She holds a PharmD and an MSc (Pharmacy) from Utrecht University and is ACMA/CGMA qualified.
- Steven Baert
-
Steven Baert，自分拆以来一直担任GE Vernova Inc.的首席人事官，在分拆之前，从2023年4月起担任GE Vernova业务的首席人事官，直到分拆。最近在2021年9月至2023年3月期间，Baert先生为风险资本和私募股权公司提供人力资本事务方面的建议，最初担任Flagship Pioneering Inc.（一家专注于生命科学的风险投资公司）的人力资本官和高级合伙人，随后担任Propuli GmbH（一家管理咨询公司）的管理合伙人。此外，从2014年到2021年9月，Baert先生曾担任Novartis（纽约证券交易所代码：NVS）的首席人员和组织官兼执行委员会成员。Baert先生在公司内担任多个领导职务，包括新兴增长市场人力资源主管、美国和加拿大人力资源主管、Novartis Oncology人力资源全球主管。在加入Novartis之前，Baert先生在Bristol-Myers Squibb Co.（纽约证券交易所代码：BMY）和Unilever（纽约证券交易所代码：UL）担任高级人力资源职位。Baert先生还担任Pharming Group N.V。 （Nasdaq： PHAR）董事会的非执行董事、薪酬委员会主席和公司治理委员会成员，并担任Servier SAS（法国制药公司）监事会的非执行董事。Baert先生持有根特的弗列里克商学院的工商管理硕士学位；获得Katholieke Leuven大学法学硕士学位和Katholieke Brussels大学法学学士学位。
Steven Baert Chief People Officer. Mr. Baert has served as the Chief People Officer of GE Vernova since the Spin Off, and prior to the Spin Off, served as the Chief People Officer of the GE Vernova businesses from April 2023 until the Spin Off. Most recently between September 2021 and March 2023, Mr. Baert advised venture capital and private equity companies on human capital matters, initially as Human Capital Officer and Senior Partner of Flagship Pioneering Inc., a life sciences focused venture capital company, and subsequently as managing partner of Propuli GmbH, a management consulting business. Additionally, Mr. Baert previously served as Chief People & Organization Officer and Member of the Executive Committee of Novartis (NYSE: NVS) from 2014 until September 2021. Mr. Baert held a number of leadership roles within the company, including Head of Human Resources for Emerging Growth Markets, Head of Human Resources, United States and Canada, and Global Head, Human Resources, Novartis Oncology. Prior to joining Novartis, Mr. Baert held senior HR positions at Bristol Myers Squibb Co. (NYSE: BMY) and Unilever (NYSE: UL). Mr. Baert also serves as a non executive director, chair of the remuneration committee and member of the corporate governance committee on the board of directors of Pharming Group N.V. (Nasdaq: PHAR) and serves as a non executive director of the supervisory board of Servier SAS, a French pharmaceuticals company. Mr. Baert holds a Master of Business Administration from the Vlerick Business School, Gent; a Master of Laws from the Katholieke Universiteit Leuven and a Bachelor of Laws from the Katholieke Universiteit Brussels. - Steven Baert，自分拆以来一直担任GE Vernova Inc.的首席人事官，在分拆之前，从2023年4月起担任GE Vernova业务的首席人事官，直到分拆。最近在2021年9月至2023年3月期间，Baert先生为风险资本和私募股权公司提供人力资本事务方面的建议，最初担任Flagship Pioneering Inc.（一家专注于生命科学的风险投资公司）的人力资本官和高级合伙人，随后担任Propuli GmbH（一家管理咨询公司）的管理合伙人。此外，从2014年到2021年9月，Baert先生曾担任Novartis（纽约证券交易所代码：NVS）的首席人员和组织官兼执行委员会成员。Baert先生在公司内担任多个领导职务，包括新兴增长市场人力资源主管、美国和加拿大人力资源主管、Novartis Oncology人力资源全球主管。在加入Novartis之前，Baert先生在Bristol-Myers Squibb Co.（纽约证券交易所代码：BMY）和Unilever（纽约证券交易所代码：UL）担任高级人力资源职位。Baert先生还担任Pharming Group N.V。 （Nasdaq： PHAR）董事会的非执行董事、薪酬委员会主席和公司治理委员会成员，并担任Servier SAS（法国制药公司）监事会的非执行董事。Baert先生持有根特的弗列里克商学院的工商管理硕士学位；获得Katholieke Leuven大学法学硕士学位和Katholieke Brussels大学法学学士学位。
- Steven Baert Chief People Officer. Mr. Baert has served as the Chief People Officer of GE Vernova since the Spin Off, and prior to the Spin Off, served as the Chief People Officer of the GE Vernova businesses from April 2023 until the Spin Off. Most recently between September 2021 and March 2023, Mr. Baert advised venture capital and private equity companies on human capital matters, initially as Human Capital Officer and Senior Partner of Flagship Pioneering Inc., a life sciences focused venture capital company, and subsequently as managing partner of Propuli GmbH, a management consulting business. Additionally, Mr. Baert previously served as Chief People & Organization Officer and Member of the Executive Committee of Novartis (NYSE: NVS) from 2014 until September 2021. Mr. Baert held a number of leadership roles within the company, including Head of Human Resources for Emerging Growth Markets, Head of Human Resources, United States and Canada, and Global Head, Human Resources, Novartis Oncology. Prior to joining Novartis, Mr. Baert held senior HR positions at Bristol Myers Squibb Co. (NYSE: BMY) and Unilever (NYSE: UL). Mr. Baert also serves as a non executive director, chair of the remuneration committee and member of the corporate governance committee on the board of directors of Pharming Group N.V. (Nasdaq: PHAR) and serves as a non executive director of the supervisory board of Servier SAS, a French pharmaceuticals company. Mr. Baert holds a Master of Business Administration from the Vlerick Business School, Gent; a Master of Laws from the Katholieke Universiteit Leuven and a Bachelor of Laws from the Katholieke Universiteit Brussels.
高管简历
中英对照 | 中文 | 英文- Sijmen de Vries
Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom).- Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
- Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom).
- Mireille Sanders
Mireille Sanders，在2020年12月15日被任命为首席运营官之前，Sanders女士自2019年起担任我们的运营高级副总裁。从2016年到2019年，Sanders女士担任强生公司公司Janssen Pharmaceuticals的临床供应链战略管理和系统主管。在加入Janssen之前，Sanders女士于2007年至2015年在MSD/Merck担任高级职务。她拥有荷兰埃因霍温工业大学的化学工程硕士学位。
Mireille Sanders oversees Pharming's end to end operations, from development and manufacturing to quality and distribution of commercial and clinical supplies. Mireille joined Pharming as Senior Vice President of Operations in 2019. Mireille also represents Pharming on the Supervisory Board of BioConnection, a Netherlands based CDMO specializing in sterile injectable manufacturing. She holds an MSc in Chemical Engineering from the Technical University of Eindhoven (TU/e), the Netherlands.- Mireille Sanders，在2020年12月15日被任命为首席运营官之前，Sanders女士自2019年起担任我们的运营高级副总裁。从2016年到2019年，Sanders女士担任强生公司公司Janssen Pharmaceuticals的临床供应链战略管理和系统主管。在加入Janssen之前，Sanders女士于2007年至2015年在MSD/Merck担任高级职务。她拥有荷兰埃因霍温工业大学的化学工程硕士学位。
- Mireille Sanders oversees Pharming's end to end operations, from development and manufacturing to quality and distribution of commercial and clinical supplies. Mireille joined Pharming as Senior Vice President of Operations in 2019. Mireille also represents Pharming on the Supervisory Board of BioConnection, a Netherlands based CDMO specializing in sterile injectable manufacturing. She holds an MSc in Chemical Engineering from the Technical University of Eindhoven (TU/e), the Netherlands.
- Anurag Relan
阿努拉格·雷兰，在2021年6月被任命为首席医疗官之前，雷兰先生一直担任临床研究和医疗事务副总裁，过去15年在公司担任过多个职务。在Pharming工作之前，他从事临床实践，同时也教授住院医生和学生。Relan先生拥有加州大学洛杉矶分校的医学博士和公共卫生硕士学位，以及加州大学伯克利分校的经济学学士学位。
Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming's global medical strategy, including clinical development, regulatory engagement, patient safety, and medical affairs. Previously, as Vice President of Clinical Research and Medical Affairs, Anurag began his career in clinical practice and academic medicine, teaching residents and medical students at the University of California, Los Angeles Medical Center, and he continues to practice as a physician. He has co authored more than 30 publications in leading peer reviewed medical journals, many focused on hereditary angioedema and rare disease. He holds an M.D. and a Master of Public Health (M.P.H.) from the University of California, Los Angeles, and a bachelor's degree in economics from the University of California, Berkeley.- 阿努拉格·雷兰，在2021年6月被任命为首席医疗官之前，雷兰先生一直担任临床研究和医疗事务副总裁，过去15年在公司担任过多个职务。在Pharming工作之前，他从事临床实践，同时也教授住院医生和学生。Relan先生拥有加州大学洛杉矶分校的医学博士和公共卫生硕士学位，以及加州大学伯克利分校的经济学学士学位。
- Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming's global medical strategy, including clinical development, regulatory engagement, patient safety, and medical affairs. Previously, as Vice President of Clinical Research and Medical Affairs, Anurag began his career in clinical practice and academic medicine, teaching residents and medical students at the University of California, Los Angeles Medical Center, and he continues to practice as a physician. He has co authored more than 30 publications in leading peer reviewed medical journals, many focused on hereditary angioedema and rare disease. He holds an M.D. and a Master of Public Health (M.P.H.) from the University of California, Los Angeles, and a bachelor's degree in economics from the University of California, Berkeley.
- Ruud van Outersterp
范奥特斯特普，在2021年5月1日被任命为首席道德与合规官之前，范奥特斯特普先生从2020年4月1日起担任Pharming Group N.V.公司秘书。在加入Pharming公司之前，van Outersterp先生曾在荷兰银行及其前任担任多个高级领导职务，包括全球法律主管和公司秘书，并在前荷兰飞机制造商福克公司担任高级法律顾问。van Outersterp先生也是一家医疗保健机构的监事会成员，并且是荷兰德里伯根治理大学的教师。他在阿姆斯特丹自由大学获得了法学硕士学位。
Ruud van Outersterp was updated in 2025 to Chief Legal and Compliance Officer and Company Secretary. He leads Pharming's global legal, compliance, and governance activities, ensuring Pharming operates with integrity across drug development and commercialization. Ruud first joined Pharming in 2020 as Company Secretary, and held that role until April 2022, strengthening corporate governance, board processes, and regulatory compliance. He has more than 35 years of legal leadership experience across financial services, aerospace, and life sciences. Prior to Pharming, he held several senior roles at ABN AMRO and its predecessors, including Global Head of Legal and Company Secretary. In addition to his executive role, Ruud serves on the Supervisory Board of a Dutch healthcare institution providing a broad range of care services, primarily to elderly individuals and people with physical disabilities, and he teaches corporate governance at the Governance Academy in the Netherlands. He holds a Master of Laws (LLM) from the Vrije Universiteit Amsterdam.- 范奥特斯特普，在2021年5月1日被任命为首席道德与合规官之前，范奥特斯特普先生从2020年4月1日起担任Pharming Group N.V.公司秘书。在加入Pharming公司之前，van Outersterp先生曾在荷兰银行及其前任担任多个高级领导职务，包括全球法律主管和公司秘书，并在前荷兰飞机制造商福克公司担任高级法律顾问。van Outersterp先生也是一家医疗保健机构的监事会成员，并且是荷兰德里伯根治理大学的教师。他在阿姆斯特丹自由大学获得了法学硕士学位。
- Ruud van Outersterp was updated in 2025 to Chief Legal and Compliance Officer and Company Secretary. He leads Pharming's global legal, compliance, and governance activities, ensuring Pharming operates with integrity across drug development and commercialization. Ruud first joined Pharming in 2020 as Company Secretary, and held that role until April 2022, strengthening corporate governance, board processes, and regulatory compliance. He has more than 35 years of legal leadership experience across financial services, aerospace, and life sciences. Prior to Pharming, he held several senior roles at ABN AMRO and its predecessors, including Global Head of Legal and Company Secretary. In addition to his executive role, Ruud serves on the Supervisory Board of a Dutch healthcare institution providing a broad range of care services, primarily to elderly individuals and people with physical disabilities, and he teaches corporate governance at the Governance Academy in the Netherlands. He holds a Master of Laws (LLM) from the Vrije Universiteit Amsterdam.
- Leverne Marsh
Leverne Marsh领导Pharming在市场准入、营销、销售和生命周期管理方面的全球商业战略。她将深厚的商业专业知识与应用人工智能和分析塑造客户洞察力的实践经验相结合，利用这些技能加强Pharming与其服务的患者之间的联系。Leverne带来了近30年的生命科学商业领导地位。她曾在诺华担任高级职务，领导主要产品发布并担任首席产品官和战略主管，在德康医疗担任执行副总裁，负责营销、推动增长和国际扩张。作为一名受过训练的药剂师，Leverne开始了她的药学生涯，并持有南非伊丽莎白港大学的BPharm。
Leverne Marsh leads Pharming's global commercial strategy across market access, marketing, sales, and lifecycle management. She combines deep commercial expertise with practical experience applying AI and analytics to shape customer insight, using those skills to strengthen the connection between Pharming and the patients it serves. She has held senior roles at Novartis, where she led major product launches and served as Chief Product Officer and Head of Strategy, and at Dexcom, where she was Executive Vice President, Marketing, driving growth and international expansion. A trained pharmacist, Leverne began her career in pharmacy and holds a BPharm from the University of Port Elizabeth, South Africa.- Leverne Marsh领导Pharming在市场准入、营销、销售和生命周期管理方面的全球商业战略。她将深厚的商业专业知识与应用人工智能和分析塑造客户洞察力的实践经验相结合，利用这些技能加强Pharming与其服务的患者之间的联系。Leverne带来了近30年的生命科学商业领导地位。她曾在诺华担任高级职务，领导主要产品发布并担任首席产品官和战略主管，在德康医疗担任执行副总裁，负责营销、推动增长和国际扩张。作为一名受过训练的药剂师，Leverne开始了她的药学生涯，并持有南非伊丽莎白港大学的BPharm。
- Leverne Marsh leads Pharming's global commercial strategy across market access, marketing, sales, and lifecycle management. She combines deep commercial expertise with practical experience applying AI and analytics to shape customer insight, using those skills to strengthen the connection between Pharming and the patients it serves. She has held senior roles at Novartis, where she led major product launches and served as Chief Product Officer and Head of Strategy, and at Dexcom, where she was Executive Vice President, Marketing, driving growth and international expansion. A trained pharmacist, Leverne began her career in pharmacy and holds a BPharm from the University of Port Elizabeth, South Africa.
- Kenneth Lynard
Kenneth Lynard已担任Pharming的首席财务官或首席财务官。他曾在美国和欧洲担任高级财务职务，既支持老牌制药公司，也支持处于成长阶段的生物制药组织。在加入Pharming之前，Kenneth曾担任Schoeller Allibert的首席财务官，此前曾在Zentiva和Affidea担任首席财务官职位，这两家公司都是私募股权支持的公司。在吉利德科学职业生涯的早期，他曾担任负责全球商业运营、研发和制造的财务高级副总裁，为向新的治疗领域和市场进行重大转型和扩张做出了贡献。Kenneth的公共会计职业生涯始于Arthur Andersen，之后在美敦力、康乐保和Superfos担任高级财务领导职务。他拥有哥本哈根商学院商业经济学和审计的理学硕士学位（MSC），以及瑞士洛桑IMD的高级管理人员MBA学位。
Kenneth Lynard has served as Chief Financial Officer, or CFO, of Pharming. He has held senior finance roles across the United States and Europe, supporting both established pharmaceutical companies and growth stage biopharmaceutical organizations. Prior to joining Pharming, Kenneth served as CFO of Schoeller Allibert and previously held CFO positions at Zentiva and Affidea, both Private Equity backed companies. Earlier in his career at Gilead Sciences, he served as Senior Vice President Finance for Global Commercial Operations, R&D, and Manufacturing, contributing to a period of significant transformation and expansion into new therapeutic areas and markets. Kenneth began his career in public accounting at Arthur Andersen before moving into senior finance leadership roles at Medtronic, Coloplast, and Superfos. He holds a Master of Science (MSc) in Business Economics and Auditing from Copenhagen Business School and an Executive MBA from IMD in Lausanne, Switzerland.- Kenneth Lynard已担任Pharming的首席财务官或首席财务官。他曾在美国和欧洲担任高级财务职务，既支持老牌制药公司，也支持处于成长阶段的生物制药组织。在加入Pharming之前，Kenneth曾担任Schoeller Allibert的首席财务官，此前曾在Zentiva和Affidea担任首席财务官职位，这两家公司都是私募股权支持的公司。在吉利德科学职业生涯的早期，他曾担任负责全球商业运营、研发和制造的财务高级副总裁，为向新的治疗领域和市场进行重大转型和扩张做出了贡献。Kenneth的公共会计职业生涯始于Arthur Andersen，之后在美敦力、康乐保和Superfos担任高级财务领导职务。他拥有哥本哈根商学院商业经济学和审计的理学硕士学位（MSC），以及瑞士洛桑IMD的高级管理人员MBA学位。
- Kenneth Lynard has served as Chief Financial Officer, or CFO, of Pharming. He has held senior finance roles across the United States and Europe, supporting both established pharmaceutical companies and growth stage biopharmaceutical organizations. Prior to joining Pharming, Kenneth served as CFO of Schoeller Allibert and previously held CFO positions at Zentiva and Affidea, both Private Equity backed companies. Earlier in his career at Gilead Sciences, he served as Senior Vice President Finance for Global Commercial Operations, R&D, and Manufacturing, contributing to a period of significant transformation and expansion into new therapeutic areas and markets. Kenneth began his career in public accounting at Arthur Andersen before moving into senior finance leadership roles at Medtronic, Coloplast, and Superfos. He holds a Master of Science (MSc) in Business Economics and Auditing from Copenhagen Business School and an Executive MBA from IMD in Lausanne, Switzerland.